Funding Opportunity

  1. Home
  2. Funding Opportunity

Newspapers are one of the main tool where information are released and widely spread over the globe. Some of them are oriented to what is happening over the medial field, the different experimental work still ongoing and the recent discoveries released to the community aiming to enhance the health of the human being. 

IPOKRATE's role is to select these relevant newspaper articles from trusted sites and well known sources and automaticaly will be provided to your smartphone. Also, Ipokrate platform will share with you regularly their analysis over the medical concerns highliting their impact on the world community health.

Become a member and we will keep you up-to-date of the latest medical news.

 

EXPLORATORY GRANTS IN CANCER CONTROL (R21 CLINICAL TRIAL OPTIONAL)

The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. - October 16, 2025; June 16 and October 16, 2026; June 16 and October 16, 2027; February 16 and June 16, 2028

National Institute of Health
Through this NOFO, the NCI encourages the submission of exploratory/ developmental research grant (R21) applications that focus on different aspects of cancer control by modifying behavior, screening, and understanding etiologic factors contributing to the development of cancer, and developing ways to control cancer.

CONFIRMATORY EFFICACY CLINICAL TRIALS OF NON-PHARMACOLOGICAL AND PHARMACOLOGICAL INTERVENTIONS FOR MENTAL DISORDERS (R01 CLINICAL TRIAL REQUIRED)

Application budgets are not limited but need to reflect the actual needs of the proposed project. - October 15, 2025; February 13, June 15 and October 15, 2026; February 17, June 15 and October 15, 2027

National Institute of Health
The purpose of this NOFO is to support confirmatory efficacy testing of non-pharmacological preventive and therapeutic interventions, and under certain conditions, selected pharmacological interventions for mental disorders in adults and children through an experimental therapeutics approach.

NEUROMODULATION/NEUROSTIMULATION DEVICE DEVELOPMENT FOR MENTAL HEALTH APPLICATIONS (R01 CLINICAL TRIAL NOT ALLOWED)

Application budgets are not limited but need to reflect the actual needs of the proposed project. - October 5, 2025; February 5, June 5 and October 5, 2026; February 5, June 5 and October 5, 2027

National Institute of Health
The purpose of this NOFO is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are encouraged that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are U.S. Food and Drug Administration (FDA)-approved or cleared.

Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)

Up to $275,000 in direct costs for the two or three-year project period with no more than $200,000 in direct costs in a single year. - October 20, 2025; February 19, June 18 and October 20, 2026

National Institute of Health
This NOFO invites Exploratory/ Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genetic or genomic research. Applications may propose studies using either single or mixed methods, that break new ground, extend previous discoveries in new directions, or develop preliminary data in preparation for larger studies.

GENERAL RESEARCH GRANT

Maximum Budget (USD): $125,000 per year for 1 or 2 years - Sunday, February 15,and Saturday, August 15,2026(Letter of Intent); Wednsday, April 15 and Thursday, October 15,2026 (Application)

Friedreich's Ataxia Research Alliance (FARA)
The General Research Grant is open to qualified investigators proposing projects that align with FARA Research Priorities.

CANCER PREVENTION AND CONTROL CLINICAL TRIALS GRANT PROGRAM (R01 CLINICAL TRIAL REQUIRED)

Application budgets are not limited but need to reflect the actual needs of the proposed project. - October 5, 2025; February 5, June 5 and October 5, 2026

National Institute of Health
The National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health.

NATIONAL CANCER INSTITUTE'S INVESTIGATOR-INITIATED EARLY PHASE CLINICAL TRIALS FOR CANCER TREATMENT AND DIAGNOSIS (R01 CLINICAL TRIAL REQUIRED)

Application budgets are limited to no more than $499,999 in direct costs per year. - October 5, 2025; February 5 and June 5 and October 5, 2026.

National Institute of Health
The proposed project must involve at least 1 clinical trial related to the scientific interests of one or more of the following research programs: Cancer Therapy Evaluation Program, Cancer Imaging Program, Cancer Diagnosis Program, Radiation Research Program, Complementary and Alternative Medicine Program and/or the HIV and AIDS Malignancies Research Programs. Applicants may propose to conduct an early phase trial by itself, or in combination with another research aim(s) as appropriate.

NCSBN GRANT PROGRAM

Up to $300,000. Grant funding cannot be utilized for the reimbursement of items previously purchased, - Friday, April 03, 2026 and Friday, October 02, 2026

National Council of State Boards of Nursing (NCSBN)
The NCSBN Grant Program provides funding for scientific research projects that advance the science of nursing policy and regulation and build regulatory expertise worldwide. Research Priorities include, but are not limited to: (1) Outcome studies related to nursing regulation; (2) Nursing workforce; (3) Substance use disorders in nursing; (4) New technologies related to the profession; (5) Regulatory implications of practice innovations/new models of care delivery; (6) LPN, RN and APRN scope of practice; (7) Impact of policy on nursing

SAVING LIVES AT BIRTH IN LOW-RESOURCE SETTINGS GRANTS

$50,000 - Wednesday, 01 April, 2026 and Thursday, 01 October, 2026

Laerdal Foundation
The Board will prioritize projects relating to interventions on day of birth – including prevention of stillborn deaths. Priority will be given to applications that: (1) Extend beyond local impact, demonstrating long- term practical value and inspiring advancements in other regions or countries; (2) Have innovative approaches to more efficient education and implementation; (3) Present collaborative initiatives relating to scale-up of proven concepts; (4) Take place in the Foundation’s focus countries: Tanzania, Ethiopia, Malawi, Bangladesh, India, and Nepal.

PROJECT SUPPORT

$50,000 - Wednesday, April 01, 2026 and Thursday, October 01, 2026

Laerdal Foundation
This supports practically oriented research within its stated 2025 strategy. Applications that relate to factors 2 and 3 of the Utstein Formula for Survival – improved efficiency of education or implementation, are particularly welcome. The Foundation supports projects advancing resuscitation, trauma, and maternal/newborn care.

CLINICAL PILOT AND FEASIBILITY AWARD

Applicants may request funding of up to $80,000 per year, plus an additional twelve (12) percent indirect costs for single-center clinical studies; or up to $150,000 per year, plus twelve (12) percent indirect costs for multi- center clinical studies, fo - Thursday, April 02, 2026 (Letter of Intent); Sunday, August 16, 2026 (Application)

Cystic Fibrosis Foundation (CFF), US
Clinical Pilot and Feasibility Awards are offered to support projects involving human subjects that will develop and test new hypotheses and/or new methods (or those being applied to the problems of cystic fibrosis for the first time), and to support promising new investigators as they establish themselves in research areas relevant to cystic fibrosis. The intent of these awards is to enable investigators to collect sufficient preliminary data to determine the best strategies and methods for approaching a major question that ultimately will require assessment through a larger-scale research and/or multi-center, collaborative trial.

Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)

The combined budget for direct costs for the two-year project period may not exceed $275,000, and no more than $200,000 may be requested in any single year. - October 16, 2025; February 16 and June 16, 2026

National Institute of Health
The goal of this NOFO is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease- related dementias (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD.

ALCOHOL HEALTH SERVICES RESEARCH (R01 CLINICAL TRIAL OPTIONAL)

Direct costs may not exceed $500,000 without prior approval. - October 5, 2025; February 5 and June 5, 2026

National Institute of Health
This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.

DIVERSITY IN PARKINSON’S DISEASE RESEARCH GRANT

Up to a maximum of $75,000; 10% of the funding can be used for indirect costs. - Friday, January 30, 2026 (LOI) ; Friday, June 05, 2026 (Full application, by invitation)

American Parkinson Disease Association (APDA)
This call aims to study the health inequities and/or differences among under-studied PD communities, across the spectrum of ethnicity, ancestry, geography, socioeconomic conditions, and gender. Current research has established the following: (1) Diagnosis of PD among some under-studied communities is delayed; (2) Some under-studied communities are less likely to receive quality PD care; (3) Clinical trial enrollment among certain under-studied communities does not match their representation in the population; (4) Differences in clinical features, response to treatment, co-morbidities, prevalence, natural history, genetics and biomarkers among various under-studied PD populations have not been fully explored. Projects should address one of these four issues. Projects can be designed to detect inequities or differences, understand the reasons for the inequities or differences, or test an intervention to improve disparities.

RESEARCH GRANTS: ACADEMIC YEAR 2026-2027

Up to a maximum of $75,000, including 10% indirect costs. - Friday, January 30, 2026 (LOI) ; Friday, June 05, 2026 (Full application, by invitation)

American Parkinson Disease Association (APDA)
This call supports research aimed at developing new insights into the pathophysiology, etiology and/or treatment of PD. Grant proposals can address research questions anywhere along the pipeline from basic science to rehabilitation-focused projects. APDA seeks to promote the entry of new investigators into the field of Parkinson research, as well as to support important new ideas in the field worthy of investigation.

GRANT CYCLE FOR SCIENTIFIC RESEARCH AND CLINICAL TRIALS

Kindly refer to the link before for information on the budget of each preclinical grant. - Friday, October 24, 2025(Letter of Intent);Wednesday, April 15,2026 (Full Proposal)

Osteosarcoma Institute, US
The aim of the preclinical grants is to support innovative research that advances understanding of osteosarcoma biology, accelerate the development of new therapies, and ultimately improve patient survival and quality of life.

KYLE BRYANT TRANSLATIONAL RESEARCH AWARD

Maximum Budget (USD): $200,000 per year for 1 or 2 years - Sunday, February 15, 2026(Letter of Intent); Wednsday, April 15, 2026 (Application)

Friedreich's Ataxia Research Alliance (FARA)
The Kyle Bryant Translational Research Award honors its namesake for his diligent efforts to aid the rapid translation of basic research discoveries into clinical applications. Eligible applications should focus on accelerating completion of translational stage activities necessary for advancement to clinical study of a therapeutic candidate or development of novel tools that address a critical bottleneck to the discovery or development of therapies. The specific aims must target one or more of the areas

KEITH MICHAEL ANDRUS CARDIAC RESEARCH AWARD

Maximum Budget (USD): $125,000 per year for 1 or 2 years - Sunday, February 15, 2026(Letter of Intent); Wednsday, April 15, 2026 (Application)

Friedreich's Ataxia Research Alliance (FARA)
The Keith Michael Andrus Cardiac Research Award aims to advance the understanding and treatment of cardiomyopathy associated with FA. Proposals for this award should focus on advancing understanding and/or treatment of the cardiac involvement in FA.

BRONYA J. KEATS RESEARCH COLLABORATION AWARD

Maximum Budget (USD): $175,000 per year for 1 or 2 years - Sunday, February 15, 2026(Letter of Intent); Wednsday, April 15, 2026 (Application)

Friedreich's Ataxia Research Alliance (FARA)
Proposals should focus on FA research that relies on collaboration among investigators from at least two different institutions. Special consideration will be given to proposals that involve international collaborations and bring new scientists to the FA community. The rationale for the collaboration needs to be convincing: it must clearly demonstrate that the research goals could not be achieved by just one of the participating groups and the synergy among the groups is essential for the success of the project.

CHILDHOOD CANCER THERAPEUTIC CATALYST

Up to £250,000 - April 2026 (date to be confirmed)

CANCER RESEARCH UK
The Childhood Cancer Therapeutic Catalyst accelerates the translation of discovery research into novel therapeutics. They invite applications for early drug discovery proposals from across all childhood cancer indications and modalities.

DISCOVERY AWARDS

£3.5 million. Applications above £5 million will be subject to additional scrutiny. - Tuesday,March 31, 2026

Wellcome Trust
This scheme provides funding for established researchers/teams from any discipline who want to pursue bold/creative research ideas to deliver significant shifts in understanding related to human life, health and wellbeing.

CAREER DEVELOPMENT AWARDS - 2026

Usually below £250,000 - Thursday, March 26, 2026

Wellcome Trust
This scheme provides funding for mid-career researchers from any discipline who have the potential to beinternational research leaders. They will develop their research capabilities, drive innovative programmes of work and deliver significant shifts in understanding related to human life, health and wellbeing.

TRANSLATIONAL STRATEGIES TO DEFINE, ENHANCE, AND MONITOR VASCULARIZATION FOR DURABLE ISLET REPLACEMENT THERAPIES

Up to $900,000 for a maximum duration of three years. - Wednesday, January 28, 2026(Letter of Intent); Wednesday, March 11, 2026 (Application); Informational Webinar on Jan, 13 2026 (12 p.m. ET)

Breakthrough T1D, US
This funding opportunity aims to support translational research that advances the clinical application of vascularization- and engraftment-focused strategies for islet replacement therapy in type 1 diabetes (T1D). Funded projects must address at least one of the following areas: 1) define vascular features that correlate with or predict graft function and long-term durability; 2) advance strategies to enhance vascular integration, perfusion and graft resilience at extrahepatic transplant sites; or 3) advance non- invasive technologies to monitor neovascularization, perfusion, vascular stability, and oxygenation in vivo.

IN VITRO DISEASE MODELING: TYPE I DIABETES-ON-A-CHIP PLATFORMS FOR TRANSLATIONAL RESEARCH

Up to $300,000 over one year - Friday, January 28, 2026(Letter of Intent);Wednesday, March 11,2026 (Application);Informational Webinar on Jan, 13 2026 (12 p.m. ET)

Breakthrough T1D, US
This funding opportunity aims to support advancement of cutting-edge organoid- and organ on a chip-based disease models of Type I Diabetes (T1D). This initiative aims to validate and refine existing human-relevant in vitro models of T1D as tools for evaluation of pharmacological and genetic interventions with the goal of accelerating translation to clinical studies.

Voices Through Time – 1st Cycle

Each award is up to QAR 547.500 per year for up to two years. - Wednesday January 14, 2026 Submission opens, Wednesday March 11, 2026 Submission deadline

Qatar Research Development and Innovation Council (QRDI)
The call aims to address the following research priorities: ·National Collection- Documentation and Analysis · National Collection - Utilization and Outreach · The Economics of Heritage

Artificial Intelligence For Qatar – 1st Cycle

Each award is up to QAR 500.000 per year for up to two years. - Wednesday, 14 January, 2026 Submission opens and Wednesday, 11 March 2026 Submission deadline

Qatar Research Development and Innovation Council (QRDI)
The call aims to address the following research priorities: · Artificial Intelligence Assisted Healthcare · Artificial Intelligence Assisted Education · Artificial Intelligence Assisted Tourism

SEHATech – 1st Cycle

Each award is up to QAR 547.500 per year for up to three years. - Wednesday, 11 March, 2026

Qatar Research Development and Innovation Council (QRDI)
The call aims to address the following research priorities: - Enhancing Interoperability and Standardization - Advancing Data Management - Harnessing AI, Informatics, and Smart Technologies

Future Communications – 1st Cycle

Each award is up to QAR 500.000 per year for up to two years. - Wednesday, 11 March, 2026

Qatar Research Development and Innovation Council (QRDI)
The call aims to address the following research priorities: · AI-powered networks for secure, efficient, and adaptive telecommunications ·Exploring how 6G technologies can expand/enhance daily-life applications beyond the capabilities of 4G/5G · Advancing research on the challenges and solutions for seamless hybrid satellite/cellular/fiber networks ·Investigating quantum computing penetration and its implications for existing network architectures

Advancing Neuro and Mental Health Research – 2nd Cycle

Each award is up to QAR 547.500 per year for up to two years. - Wednesday, 11 March, 2026

Qatar Research Development and Innovation Council (QRDI)
The call aims to address the following research priorities: · Epidemiological Studies on Mental and Neurological Disorders in Qatar · Precision Mental and Neurological Health · Emerging Technologies for Mental and Neurological Health . Neuromodulation and Behavioral Therapies · Neurodevelopmental Research and Early Interventions

Path Towards Precision Medicine – 9th Cycle

Each award is up to QAR 800,000 per year for up to three years. - Wednesday, 11 March, 2026

Qatar Research Development and Innovation Council (QRDI)
The call aims to address the following research priorities: · Artificial Intelligence, Informatics, and Technology Solutions in Precision Medicine · Disease Risk Stratification in Population Groups · Integration of Genomics and other Omics in Clinical Diagnostics · Pharmacogenomics from Discovery to Implementation

Climate Change and Environment – 3rd Cycle

Each award is up to QAR 547.500 per year for up to two years - Wednesday, 11 March, 2026

Qatar Research Development and Innovation Council (QRDI)
The call aims to address the following research priority: · Biodiversity

Food Security– 6th Cycle

Each award is up to QAR 533.000 per year for up to three years. - Wednesday, 11 March, 2026

Qatar Research Development and Innovation Council (QRDI)
The call aims to address the following research priority: · Smart Integrated Disease Management (IDM) for Protected Vegetable Production · Resilient, Traceable, and Allergen-Safe Supply Chains for Specialty-Nutrition Foods · Agricultural policies and Agricultural Extension · Digital Agriculture and Food System Innovation

PILOT CLINICAL TRIAL GRANTS

Each Grant will be 2-4 years in duration, with a maximum total Grant Award up to $1,000,000. - November 28, 2025 (LOI); February 27, 2026 (RFP)

International Waldenstrom's Macroglobulinemia Foundation (IWMF)
The aim is to support investigator-initiated trials to undertake (1) innovative clinical studies using novel agents, novel combination therapies, or immunotherapies with high potential for clinical activity in WM; and (2) studies that substantially improve quality of life and/or reduce prevalent disease complications. It is seeking distinctly novel advances and innovative approaches.

TRANSLATIONAL RESEARCH GRANTS

Each grant will be 3-4 years in duration, with a maximum total Grant Award from $500,000 to $750,000. - November 28, 2025 (LOI); February 27, 2026 (RFP)

International Waldenstrom's Macroglobulinemia Foundation (IWMF)
The IWMF seeks proposals to understand the mechanisms of Waldenstrom macroglobulinemia pathogenesis with a focus on (1) uncovering new features of WM biology and cellular vulnerabilities; (2) laboratory studies investigating mechanisms of WM relapse and therapy resistance; and (3) identifying novel, therapeutically exploitable targets that represent previously under-explored opportunities. Such foundational studies should be focused on translational potential and ultimately driven by the goals of improved patient outcomes and reduction or elimination of disease.

CORRELATIVE COMPANION RESEARCH GRANTS

Each Grant will be 2 years in duration, with a maximum total Grant Award of up to $250,000. - November 28, 2025 (LOI); February 27, 2026 (RFP)

International Waldenstrom's Macroglobulinemia Foundation (IWMF)
IWMF seeks to support correlative companion research studies within pharmaceutical and biotechnology company-sponsored trials for Waldenstrom macroglobulinemia patients that will be instrumental in determining the optimal use of new therapeutics under study. These projects leverage biological samples collected during trials to explore and validate biomarkers, mechanisms of response or resistance, or disease biology response to therapeutic intervention that will inform future clinical studies. Projects may include identifying genetic, proteomic, or immune markers that predict activity profiles, elucidating molecular mechanisms of resistance, TME profiling, MRD assessment, among others.

ACCELERATION AND EXPANSION RESEARCH GRANTS

Each Grant will be one year in duration, with the IWMF retaining the option to renew the Grant for an additional year, for a maximum total Grant Award of $250,000 over 2 years. - November 28, 2025 (LOI); February 27, 2026 (RFP)

International Waldenstrom's Macroglobulinemia Foundation (IWMF)
These grants aim to support research studies to (1) accelerate existing and additional IWMF Grants requiring further funding based on a novel, testable hypothesis that drives the additional funded research work toward translational and clinical applications (an Acceleration Grant); or (2) expand funding support for novel, translational mechanisms or targets, based on previous proof-of-concept work that may or may not have previous evidence of activity in B-cell malignancies (an Expansion Grant).

ROBERT A. KYLE CAREER DEVELOPMENT AWARD GRANT

The maximum total Grant Award costs may be up to $160,000, inclusive of 5% for indirect costs. - November 28, 2025 (LOI); February 27, 2026 (RFP)

International Waldenstrom's Macroglobulinemia Foundation (IWMF)
The aim of this grant is to provide support to talented young investigators with a background in hematology and/or oncology, encouraging them to either enter or continue WM research. A successful applicant’s academic program must have a formal teaching curriculum and mentoring from established investigators with a proven record of advancing relevant research in the B-cell malignancy or plasma cell malignancy field.

GRANT PROGRAM

$150,000, indirect costs of up to 8% are allowed. - Friday, February 27, 2026 (LOI)

Foundation for Prader-Willi Research
The Foundation for Prader-Willi Research (FPWR) is dedicated to supporting research to advance the understanding and treatment of Prader-Willi syndrome (PWS). Briefly, funding priority areas include: (1) Genotype to phenotype: understanding PWS genetics / how loss of PWS-critical region genes leads to the phenotype, (2) Neurobiology of hunger / feeding behavior and metabolism in PWS, (3) Neurobiology of cognition, maladaptive behavior, and mental health in PWS, (4) Clinical care research: evaluation of existing drugs and interventions to improve the significant clinical concerns in PWS and (5) Therapeutics development for PWS- Genetic therapies; novel or repurposed pharmaceuticals; and devices

NEUROIMAGING AND CSF BIOMARKER PROGRAM

Up to $600,000 based on stage and scope of research.Only direct costs are allowed. - Monday, February 23, 2026 (LOI)

Alzheimer's Drug Discovery Foundation
The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use. Specifically, this RFP focuses on: (1) Developing novel PET ligands for clinical trials, (2) Supporting novel CSF biomarkers, (3) Validating innovative MRI approaches in larger cohorts and (4) Developing novel measures of functional activity such as EEG

WELLCOME EARLY-CAREER AWARDS

The salary of the early-career researcher and up to £400,000 for research expenses. - Tuesday, February 17, 2026

Wellcome Trust
This scheme provides funding for early-career researchers from any discipline who are ready to develop their research identity. Through innovative projects, they will deliver shifts in understanding related to human life, health and wellbeing. By the end of the award, they will be ready to lead their own independent research programme.

NIDCR SMALL RESEARCH GRANTS FOR ANALYSES OF EXISTING GENOMICS DATA (R03 CLINICAL TRIAL NOT ALLOWED)

The combined budget for direct costs for the two-year project period may not exceed $200,000. No more than $100,000 direct costs may be requested in any single year. - October 16, 2025 and February 16, 2026

National Institute of Health
The purpose of this NOFO is to announce support for meritorious research projects that address research questions relevant to human dental, oral, or craniofacial (DOC) biology, and diseases and conditions, through analysis of existing and publicly available genomic data, with or without other types of complementary data, using statistical and computational approaches. Projects aimed at understanding oral health disparities to inform strategies for improving health for all individuals are a priority. Projects focused on investigating and/or characterizing human biological pathways to inform identification of intervention targets or defining the pathogenicity of known genetic variants are encouraged.

EFFICIENT AND INNOVATIVE NATURAL HISTORY STUDIES ADDRESSING UNMET NEEDS IN RARE DISEASES (R01 CLINICAL TRIALS OPTIONAL)

YR 01: $400,000; YR 02: $400,000; YR 03: $400,000; YR 04: $400,000 - YR 01: $150,000; YR 02: $150,000 - Tuesday, February 10, 2026

National Institute of Health
The purpose of this notice of funding opportunity (NOFO) is to support efficient and innovative natural history studies that advance medical product development in rare diseases/conditions with unmet needs. Through the support of natural history studies with high quality and interpretable data elements, FDA expects to address critical knowledge gaps, remove major barriers to progress in the field, exert a significant and broad impact on a specific rare disease or multiple rare diseases with similar pathophysiology, and facilitate rare disease product development.

NEW INVESTIGATOR RESEARCH GRANT PROGRAM

The maximum funding request is $150k over a two year period. Indirect cost recovery or institutional overhead costs are not provided. - Friday, February 6, 2026 (Letter of Intent); April 13, 2026 (Application, by invitation only)

Leukemia Research Foundation
This grant supports early-career investigators of exceptional creativity who propose highly innovative research projects with the potential to impact broad, essential areas of leukemia research. For the program to support the best and brightest minds, applications are sought from investigators who reflect the full diversity of the research workforce and represent diverse backgrounds, institutions, and geographic locations.

THERAPEUTIC CATALYST

Up to £250k (Expression of Interest) - Thursday, February 02, 2026

CANCER RESEARCH UK
The Therapeutic Catalyst accelerates the translation of laboratory discoveries into novel cancer therapeutics. This scheme aims to de-risk early projects to facilitate further drug discovery research, funding, or partnering. They are seeking projects with strong therapeutic potential to deliver patient benefit. They invite applications for early drug discovery proposals from across all cancer indications and modalities.

TRANSLATIONAL RESEARCH GRANTS - 2026

Applicants may request up to $100,000 (direct costs only) per year. - Friday, January 30, 2026

National Psoriasis Foundation (NPF)
The NPF is seeking grant applications that encourage the advancement of innovative research into psoriasis and psoriatic arthritis. Translational Research Grants fund research projects that focus on the rapid translation of basic scientific discoveries into clinical applications with a clear benefit for patients with psoriatic disease. Review of projects prioritizes applications with a thoughtful perspective of the translational pathway that will be required to advance the proposed aims towards clinical reality. Commitments to interinstitutional or interdisciplinary research are emphasized.

DISCOVERY GRANTS - 2026

Applicants may request up to $75,000 (direct costs only) per year. - Friday, January 30, 2026

National Psoriasis Foundation (NPF)
The NPF is seeking grant applications that encourage the advancement of innovative research into psoriatic disease and related comorbidities. Discovery Grants fund researchers to explore preliminary ideas and conduct proof-of-concept experiments. Review of projects prioritizes meaningful collaborations that offer the potential to bring significant new lines of inquiry to understanding root causes and potential cures for psoriatic disease.

CAREER DEVELOPMENT AWARD

Each five-year award will be for a total of $375,000, received as five annual payments of $75,000. Budgets can be tailored to address the situations of individual recipients. - Thursday, January 29, 2026

Foundation Fighting Blindness (FFB), US
The award’s goal is to help advance junior clinical research scientists in their professional endeavors to cure retinal degenerative disease by: (1) facilitating advances in laboratory and clinical research; (2) elucidating the mechanism for the cause and pathogenesis of retinal degenerative diseases; (3) developing innovative strategies to prevent, treat and cure these diseases.

ANN THEODORE FOUNDATION BREAKTHROUGH SARCOIDOSIS INITIATIVE

For detailed eligibility notes, please refer to the link above. - Monday, January 19, 2026

Milken Institute
ATF-BSI welcomes proposals to investigate sarcoidosis regardless of organ system. The scientific focus of ATF- BSI proposals should address one or more of the suggested focus areas.

LLOYD J. OLD STAR PROGRAM

$1.25M over a 5 year period. Institutions will receive up to 10% indirect costs on top of awarded funds. - Thursday, January 15, 2026

Cancer Research Institute
The CRI Lloyd J. Old STAR Program — Scientists TAking Risks — provides long-term, flexible funding to mid-career scientists, giving them the freedom to pursue high-risk, high-reward research at the leading edge of cancer immunotherapy.

IFCAH-ESPE GRANTS

Selected research projects will be supported up to EUR 150k (total). - Thursday, December 15, 2026(LOI)

European Society for Paediatric Endocrinology (ESPE)
IFCAH aims to develop better ways to treat CAH (Congenital Adrenal Hyperplasia), allowing people to live better, healthier lives. Specific goals are available at the link below.

DIPG RESEARCH GAME CHANGER GRANT

Up to $600,000 over 3 years (maximum of $200,000 per year). - Monday January 12, 2026 (LOI)

ChadTough Defeat DIPG Foundation
This grant provides three years of funding for hypothesis-driven research projects. The proposed research must represent an innovative approach to a major challenge in DIPG/DMG research. The funded projects must have the potential to lead to groundbreaking discoveries in the field and transform our understanding of the tumorigenesis process or our ability to treat or detect DIPG.

DIPG RESEARCH NEW INVESTIGATOR GRANT

Up to $400,000 over 3 years (maximum of $135,000 in any one year). - Monday January 12, 2026 (LOI)

ChadTough Defeat DIPG Foundation
This grant provides three years of funding to a new DIPG/DMG investigator for hypothesis-driven research projects. The investigator may be either a newly independent researcher establishing a new DIPG/DMG research lab, or an established researcher who has not previously conducted brain tumor research.

QUARTERLY RESEARCH GRANT FUNDING PROGRAMME

For preclinical research, grants up to £250,000 (GBP) are funded and priority is given to projects that are likely to lead to clinical trials in people with Parkinson’s within 5 years. - Monday January 12, 2026

Cure Parkinson's
This programme primarily funds preclinical and clinical research focused on slowing, stopping, or reversing Parkinson’s. For preclinical research, priority is given to projects that are likely to lead to clinical trials in people with Parkinson’s within 5 years. For clinical research, the funder supports clinical trials and sub-studies of trials in people with Parkinson’s. Research which is directed at symptomatic relief is not in remit.

COMMON MECHANISMS IN AUTOIMMUNITY INSIGHT AWARDS

Applicants may request budgets of up to $150K for 1 year, which includes up to 10% indirect costs. - Thursday, January 08, 2026 (Full Proposal)

Breakthrough T1D, US
Proposals are sought from academic or industry applicants for novel one-year pilot studies to investigate a mechanism underlying autoimmune disease, identify novel targets or mechanisms of autoimmune pathogenesis, validate therapeutic targets, or provide proof of concept for an innovative therapeutic strategy. Through the Insight Awards, Breakthrough T1D, Lupus Research Alliance, and the National MS Society seek to co-fund projects that will obtain more specific insights into the commonalities and differences of immune pathways that govern autoimmune disease processes and lay the groundwork for bringing together investigators from across autoimmune fields and disciplines. All project proposals should be relevant to multiple autoimmune diseases, two of which should be relevant to multiple sclerosis, systemic lupus erythematosus (or one of its manifestations), and/or type 1 diabetes. These projects should be designed to establish a proof of concept to a future expanded collaborative study and therefore should constitute “step-one” of an ambitious endeavor.

ESTABLISHING IMMUNE TOLERANCE IN ISLET CELL REPLACEMENT THERAPY FOR TYPE 1 DIABETES (T1D)

Up to a total of $900,000 for up to three years. - Wednesday January 07, 2026 (LOI); Informational Webinar and Q&A on December 16

Breakthrough T1D, US
This funding opportunity aims to support the development of tolerance induction approaches for islet cell therapy that enables graft-specific immune protection without compromising natural immune defenses. This call is open to both central and peripheral tolerance induction strategies with prioritization given to technologies closest to clinical translation.

CURE TAKING FLIGHT AWARD

$125,000 - Tuesday, January 06, 2026 (LOI)

Citizens United for Research in Epilepsy (CURE)
The Taking Flight Award seeks to promote the careers of early-career investigators to allow them to develop an independent research focus.

CLINICAL RESEARCH GRANTS

Up to $75,000 (US) per project. - Monday, January 05, 2026

INTUITIVE Foundation
The purpose of these grants is to support clinical research at non-profit institutions worldwide focused on thefield of robotic-assisted surgery. Successful proposals will study important questions related to surgical care and patient outcomes. The Intuitive Foundation has identified key research areas of interest for the 2026- 2027 clinical grant programs. Principal Investigators are encouraged – although not required – to submit proposals that fall into one or more of the those areas.

BRONCHOSCOPY RESEARCH GRANT

Up to $75,000 (US) per project. - Monday, January 05, 2026

INTUITIVE Foundation
The purpose of these grants is to support clinical research at non-profit institutions worldwide focused on the effect of robotic-assisted bronchoscopy in the clinical care of patients with pulmonary disease. Successful proposals will study important questions related to the impacts robotic-assisted bronchoscopy on disease diagnosis and or management or patient outcomes.

ACCELERATING DEVELOPMENT OF INNOVATIVE, EXCEPTIONALLY LOW-COST MATERNAL AND CHILD NUTRIENT INGREDIENTS AND PRODUCTS

Option 1: Up to $500,000 per ingredient, Up to 18 months; Option 2: Up to $200,000, Up to 12 months; Option 3: Up to $400,000, Up to 12 months - Tuesday, December 16, 2025

Bill and Melinda Gates Foundation (BMGF)
Applicants may propose projects under one of the following options: (1) Development of exceptionally low- cost nutrient ingredients (calcium, choline, DHA); (2) Development of a low-cost prenatal supplement (UNIMMAP MMS + 500 mg/day calcium); (3) Development of an advanced prenatal supplement (MMSplus: UNIMMAP MMS + 500 mg/day calcium + 100 mg/day nicotinamide + 450 mg/day choline + 200 mg/day DHA)

SCIENTIFIC RESEARCH GRANT PROGRAM

Up to $50,000. Funds may not be used for faculty salaries, travel expenses, or equipment. - Monday, December 15, 2025

The CHARGE Syndrome Foundation
The purpose of these grants is to promote (1) New biomedical research into the etiology, genetic and molecular mechanisms and treatment of CHARGE syndrome, or (2) New research into clinical and medical diagnosis and treatment of CHARGE syndrome.

RESEARCH ACCELERATING RUNX1 EXPLORATION (RARE)

$250,000 over 2 years (maximum $125,000 per year may be requested). Indirect costs are not allowed. - Thursday, December 11, 2025

Alex's Lemonade Stand Foundation for Childhood Cancer
The purpose of the grant is to fund research that will accelerate the discovery of druggable oncogenic pathways and deliver cancer interception and cancer prevention therapeutics for RUNX1-FPD children and family members. It will lead to the development of therapies for patients with RUNX1-FPD that will either intercept the transition from a precancer state (clonal hematopoiesis) to MDS/AML or prevent blood cancer.

DEVELOPMENT OF CONTINUOUS C-PEPTIDE MONITORING TECHNOLOGIES

Up to $900,000 in total funding over a maximum period of three years. Applications of increased scope (time and/or budget) will be considered where there is a strong justification. - Thursday, December 04, 2025 (LOI)

Breakthrough T1D, US
The aim is to develop continuous C-peptide monitoring (CCPM). Applications focused on early-stage development of sensor technologies, preclinical/feasibility studies and early-stage clinical evaluation of CCPM technologies will be considered. Letters of Intent (LOIs) are sought from academic and industry applicants with innovative approaches to develop CCPM technologies. Examples of research appropriate for this RFA include, but are not limited to: • Early-stage development of sensor technologies capable of continuous or high-frequency Cpeptide detection in biological fluids such as plasma or interstitial fluid. • Preclinical development and validation of CCPM systems. • Feasibility studies and early-stage clinical evaluation of CCPM technologies.

ACCELERATING THE PACE OF SUBSTANCE USE RESEARCH USING EXISTING DATA (R21 CLINICAL TRIAL NOT ALLOWED)

$275,000 for direct costs for the two-year project period. - Wednesday December 03, 2025

National Institute of Health
The purpose of this notice of funding opportunity (NOFO) is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. This NOFO encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance using behaviors and their consequences, including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV. Primary data collection is not allowed for applications in response to this NOFO.

TIME-SENSITIVE RESEARCH OPPORTUNITIES IN ENVIRONMENTAL HEALTH SCIENCES (R21 CLINICAL TRIAL NOT ALLOWED)

Application budgets are not limited but need to reflect the actual needs of the proposed project. - Wednesday October 01, 2025 and Monday December 01, 2025.

National Institute of Health
This NOFO is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data.

CLINICAL INNOVATOR GRANT

Up to USD $1 million for each clinical trial it supports. The funds may be used for salary, supplies, patient costs, correlative assays, and data analyses. - Monday, December 01, 2025 (Initial Protocol Concept)

Cancer Research Institute
The Clinical Innovator provides funding for clinician- scientists aiming to launch innovative phase I/II or phase II. clinical studies using novel immunotherapies. In addition to the merits of the clinical and scientific rationale, studies will be selected based on their novelty, feasibility, and clinical impact.

CLINIC AND LABORATORY INTEGRATION PROGRAM (CLIP) GRANTS

Up to $150,000 per year. CRI does not provide funds for indirect costs. - Monday, December 01, 2025 (LOI)

Cancer Research Institute
CLIP supports pre-clinical and translational research that can be directly applied to optimizing cancer immunotherapy in the clinic. CRI CLIP Grants are awarded to qualified scientists exploring clinically relevant questions aimed at improving the effectiveness of cancer immunotherapies.

RESEARCH GRANTS -2025

$15,000-$500,000 - Monday, December 01, 2025

Environmental Research & Education Foundation (EREF), US
EREF has established three key research priorities. The decision comes in response to the urgent need for innovative solutions and a deeper understanding of these pressing environmental challenges. The three selected areas represent some of the most significant issues affecting resource management and the environment today. (1) Climate Change Impacts/Greenhouse Gas Emissions (2) Emerging Contaminants (3) Advancing Materials Circularity & Recycling

EARLY-CAREER SCIENTIFIC RESEARCH GRANTS PROGRAM

Funding for each project is limited to a total of $100,000 or the amount requested in the application for the entire period of the project, either one year or two (not per year). - Monday, December 01, 2025

Association for the Advancement of Blood & Biotherapies, US
The AABB Foundation awards grants for investigator- initiated original research in all aspects of blood banking, transfusion medicine and biotherapies. Research content areas eligible for the grant program include the following: Immunology, Hematology, Immunohematology, Infectious Diseases, Biotherapies, and Patient Blood Management. Applications for research into innovative and new projects are a priority.

GUT MICROBIOTA INTERNATIONAL CALL FOR PROJECTS

€200,000 VAT included. Institutional Overhead (Maximum 10%). - Sunday, November 30, 2025

Biocodex Microbiota Foundation, FR
These support clinical or fundamental research projects focused on human gut microbiota related to health and disease. For the current round, project must focus on what perturbations may involve, but not exclusively, drugs, lifestyle factors, smoking, etc. The project should address mechanisms. Funding should not be used for a randomized controlled trial but can include the use/ analysis of samples collected from clinical trials.

TARGETED CALL IN HONOUR OF THE LIFE, WORK AND LEGACY OF PROF CHARIS ENG

Funding requests of up to £270,000 GBP (or the equivalent in the host institution’s local currency) will be considered, for a project of 2 to 3-years in length. - Tuesday, November 25, 2025

PTEN Research, GB
The aim is to progress the understanding of the mechanisms that contribute to the variable clinical presentation of PTEN hamartoma tumour syndrome (PHTS). Research proposals should focus on one of the following aims: (1) Explore opportunities to identify and/or undertake preliminary validation of biomarkers for PHTS that could predict symptom onset, occurrence, or progression/severity of symptoms at the individual level. (2) Elucidate the mechanisms of clinical heterogeneity that may include assessment of how different PTEN variants and other genetic, molecular, or cellular mechanisms contribute to and are associated with the clinical spectrum associated with PHTS.

COLLABORATE GRANT PROGRAM: SUPPORTING AGEING ADULTS LIVING WITH RARE DISEASES

$100,000. Individual projects requesting up to $25,000 will be considered. Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs. - Monday, November 24, 2025

Pfizer
Pfizer and the CanAge are collaborating to offer a new grant opportunity seeking grant proposals for programs that seek to explore innovative approaches to persistent challenges impacting older adults living with rare diseases, including, but not limited to: • Accelerating time to diagnosis by increasing understanding of the symptoms (including the distinctions between ageing and illness) through enhanced clinical awareness and integration of genetic testing to identify underlying conditions earlier • Supporting development of National Action Plans on Rare Disease (RD) to including solutions for the specific challenges faced by older adults and communities ageing with RD • Gathering exisiting evidence to support advocacy for closing heatlhcare gaps and drive policy change

DISCOVERY RESEARCH GRANTS

Teams of three to five scientists may apply to receive up to $1.5 million per year for three years, totaling up to $4.5 million per award. - Friday, November 21, 2025 (LOI)

Breakthrough Discoveries for Thriving with Bipolar Disorder, US (BD²)
This program supports an innovative and collaborative group of researchers working together to improve our understanding of the biological mechanisms that underlie bipolar disorder. BD2 will fund teams of multidisciplinary scientists to develop targeted and groundbreaking research applications that will examine the genetic, molecular, cellular, circuit, and/or behavioral mechanisms of bipolar disorder.

WELLCOME CAREER DEVELOPMENT AWARDS

Up to £250,000 excluding the applicant’s salary. - Thursday, November 20, 2025

Wellcome Trust
This scheme provides funding for mid-career researchers from any discipline who have the potential to be international research leaders. They will develop their research capabilities, drive innovative programmes of work and deliver significant shifts in understanding related to human life, health and wellbeing.

MDX IMPACT GRANTS

The programme provides researchers with access to Seegene’s syndromic PCR technology and development grants of up to 600,000 USD to perform clinical studies. - Thursday, November 20, 2025

Nature Portfolio, GB
The MDx Impact Grants aim to unlock the potential of PCR to democratise access to accurate diagnostic tests that improve patient outcomes. The goal is to develop tests that address unmet clinical needs. The programme provides researchers with access to Seegene’s syndromic PCR technology and development grants to perform clinical studies.

PATH TO A CURE - COLLABORATIVE RESEARCH GRANT

Total direct cost for the Collaborative Research Grant may not exceed $1,000,000 per year for up to three (3) years. - Thursday, November 20, 2025

Cystic Fibrosis Foundation (CFF), US
These grants are intended to facilitate research that will contribute to the development of new therapies or therapeutic strategies to treat CF, with an emphasis on advancing CFTR gene repair and replacement approaches. Collaborations that bring new investigators and technologies into the CF research community will be given highest priority. Proposals must include preliminary data to justify support from the Cystic Fibrosis Foundation.

WELL-BEING IN FTD PILOT GRANT

$110,000 (USD). Up to $10,000 of this amount may be applied to indirect costs. - Monday, November 17, 2025

American Foundation for Suicide Prevention (AFSP), US
The Well-Being in FTD Pilot Grant supports research to improve the well-being of persons diagnosed, families, and caregivers and to improve access to equitable, high- quality diagnosis, care, support, and research participation options. Please refer to the link below for examples of suitable research topics.

UNDERSTANDING THE FOREIGN BODY RESPONSE IN ISLET CELL REPLACEMENT: ACCELERATING CLINICAL TRANSLATION

Up to $900,000 each over a maximum duration of three years. - Monday, November 17, 2025 (LOI)

Breakthrough T1D, US
The aim is to support innovative research that advances the clinical translation of biomaterial-based immune- isolation strategies for islet cell replacement therapy in T1D. Preference will be given to proposals that: Use GMP-compatible biomaterials to enhance clinical relevance, Include benchmarking against biomaterials/devices with prior clinical testing, Use large animal models and NHPs, Involve collaborations between teams that have tested devices in preclinical models and can compile data towards better mechanistic understanding of the FBR or Build on previous clinical studies and/or explanted devices to elucidate mechanisms of human FBR

CRI TECHNOLOGY IMPACT AWARD

$600,000. Indirect costs account for up to 10% of the total amount awarded (in addition to awarded funds). - Saturday, November 15, 2025 (LOI)

Cancer Research Institute
This award provides seed funding to address the gap between technology development and clinical application of cancer immunotherapies. These grants aim to encourage collaboration between technology developers and clinical cancer immunologists and to generate the proof-of-principle of a novel platform technology in bioinformatics, ex vivo or in silico modeling systems, immunological or tumor profiling instrumentation, methods, reagents and assays, or other relevant technologies that can enable clinician scientists to generate deeper insights into the mechanisms of action of effective or ineffective cancer immunotherapie

EARLY CAREER RESEARCHER INNOVATION GRANTS

Up to $140,000 over 2 years. - Saturday, November 15, 2025

American Foundation for Suicide Prevention (AFSP), US
Grants awarded to investigators at or below the level of assistant professor. These grants must allocate a specified amount of their award for an established researcher to mentor the Early Career Researcher. AFSP is available to assist you in identifying a suitable mentor.

PILOT INNOVATION GRANTS

Up to $50,000 over 2 years. - Saturday, November 15, 2025

American Foundation for Suicide Prevention (AFSP), US
Awarded to investigators at any level, these grants provide seed funding for new projects that have the potential to lead to larger investigations. These grants typically entail feasibility studies rather than hypothesis- driven research. Examples include manual development and new biomarker development.

STANDARD RESEARCH INNOVATION GRANTS

Up to $125,000 over 2 years. - Saturday, November 15, 2025

American Foundation for Suicide Prevention (AFSP), US
Applications addressing the priorities set out by the National Action Alliance for Suicide Prevention’s Research.Prioritization Task Force are encouraged. Priority area research applications are reviewed along with the general pool of grant applications, with priority given to strong grants in the designated areas.

DISTINGUISHED INVESTIGATOR INNOVATION GRANTS

Up to $150,000 over 2 years. - Saturday, November 15, 2025

American Foundation for Suicide Prevention (AFSP), US
Grants awarded to investigators at the level of associate professor or higher with an established record of research and publications.

CONTRACEPTIVE DEVELOPMENT RESEARCH CENTERS (P50 CLINICAL TRIAL OPTIONAL)

Application budgets need to reflect the actual needs of the proposed project; the budget must not exceed $1.3 million per year in direct costs, excluding third party F&A. - Wednesday November12, 2025

National Institute of Health
The purpose of this Notice of Funding Opportunity (NOFO) is to support and facilitate multidisciplinary approaches towards the development of new and/or improved contraceptive methods for both men and women through the formation of a Contraceptive Development Research Center. This NOFO also allows the inclusion of translational studies to facilitate the pre- clinical to clinical transition and increase the likelihood of clinical success.

PARTNERSHIPS FOR DEVELOPMENT OF VACCINES TO PREVENT MYCOBACTERIUM TUBERCULOSIS INFECTION AND/OR DISEASE (R01 CLINICAL TRIAL NOT ALLOWED)

$750,000 direct costs per year and should reflect the actual needs of the project. - Friday, November 07, 2025

National Institute of Allergy and Infectious Disease
The purpose of this NOFO is to solicit research applications focused on preclinical development of lead candidate vaccines to prevent Mycobacterium tuberculosis infection and/or disease, and to increase the clinical pipeline of viable vaccine candidates.

REGULAR GRANT PROGRAMME

Up to £500,000 (investigator-initiated grants); up to £60,000 (for pilot and feasibility grants) - Tuesday, November 04, 2025 (outline applications)

World Cancer Research Fund International
The World Cancer Research Fund International invites applications for its regular grant programme. The aim of the WCRF Regular Grant Programme is to support innovative and original research into the role of diet, nutrition and physical activity in either Cancer Prevention or Cancer Survivorship.

RESEARCH GRANTS

$350,000 for full award - Saturday, November 01, 2025 (LOI)

International Essential Tremor Foundation (IETF), INT
The IETF is requesting proposals for grants addressing the etiology and pathogenesis of essential tremor. Concise, clearly written proposals that are hypothesis- driven have the best chance of being funded. Applications should focus on studies achieving one or more of the following goals: 1) A better understanding of the underlying pathophysiology of ET, including independent validation of previous findings. 2) A better understanding of the etiology of ET 3) Development or further validation of animal models of ET

SCIENTIFIC CALL FOR PROPOSALS: ASA GRANT 2026

120,000 €. Indirect costs are not allowed. - Saturday, November 01, 2025

The Angelman Syndrome Alliance (ASA)
Researchers of any country are invited to apply for research grants covering ‘basic science’ research that can help support a better understanding of Angelman Syndrome and eventually lead to new treatments tackling the genetic and molecular processes underlying the condition.

RESEARCH GRANTS: DISCOVERY AWARD

Up to $100,000 per year - Saturday, November 01, 2025 (LOI)

The GBS|CIDP Foundation International
GBS/CIDP Foundation International invites letters of intent for its Discovery Award. These support researchers who are committed to learning more about Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy and variants.

INNOVATIVE AWARDS

USD 200,000.00 which includes 10% indirect costs. These grants are not renewable. Final progress and expenditure reports are due within 75 days following the end date of the award. - Thursday, October 30, 2025 (Full Proposal)

Breakthrough T1D, US
Proposals should address key outstanding questions and have the potential to lead to a challenge or a change in the current paradigm or conventional wisdom and/or lead to a groundbreaking discovery. Preliminary data is not required in the proposal, but the underlying concept, premise or hypothesis must be plausible and testable, and the proposal must be focused with a well-defined goal that is achievable within the timeframe and amount of the award.

INNOVATORS GRANT AWARD

$100,000 - Monday, October 20, 2025

National Marfan Foundation (NMF), US
The objective of this grant is to to explore an innovative concept that has applicability to improving human health. Examples could include fundamental research, clinical research, diagnostic tests, biomarkers, biomedical engineering advances, and imaging advances.

CAREER DEVELOPMENT GRANT AWARD

$100,000 - Monday, October 20, 2025

National Marfan Foundation (NMF), US
This grant program is designed to support investigators early in their career to derive preliminary data in a key concept area that has high potential to lead to extended funding from NIH, EU, etc.

CO-INFECTION AND CANCER (R21 CLINICAL TRIAL NOT ALLOWED)

The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. - Thursday, October 16, 2025

National Institute of Health
The purpose of this Notice of Funding Opportunity (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.

DISEASE MODEL AWARD

From $300,000 to $1,000,000, distributed over a period of 3 to 5 years. - Thursday, October 16, 2025 (LOI)

Foundation Fighting Blindness (FFB), US
The Disease Model Award is designed to advance the field by developing and validating innovative models to support the scientific community in accelerating discovery. Applications must focus on disease models and their validation. Proposals primarily centered on therapeutic development research are out of scope for this program and will not be reviewed. The goal is to develop, validate, or utilize non-rodent disease models (in silico, in vitro, or in vivo) for therapeutic development for IRD and dAMD.

CALL FOR PROPOSALS FOR POLIO ERADICATION

$50,000-$300,000 - Friday, October 10, 2025

Global Polio Eradication Initiative (GPEI), CH and other funders
The Polio Research Committee is calling for research proposals supporting the Polio Endgame Strategy 2022- 2026. Research proposals supporting the strategic plan may be submitted to the Committee for review and funding. Preference will be given to proposals developed by GPEI partner agencies and their research collaborators. However, other institutions may also submit proposals if they address their research priorities.

IMPACT AWARDS

Each award provides $200,000 in total costs over 2 years ($100,000 per year). Up to 10% ($10,000 per year) of the total award may be used for indirect costs. - Friday, October 10, 2025

Parkinson's Foundation,US
This award is open to scientists with a PhD or MD, regardless of nationality or location. The Parkinson's Foundation Impact Awards are intended for researchers both established and new to the field of PD.

IN-DEPTH PHENOTYPING AND RESEARCH USING IMPC-GENERATED KNOCKOUT MOUSE STRAINS EXHIBITING EMBRYONIC OR PERINATAL LETHALITY OR SUBVIABILITY (R01 CLINICAL TRIAL NOT ALLOWED)

Budgets with direct costs of up to $499,999 per year may be requested - Sunday, October 05, 2025

National Institute of Health
The purpose of this NOFO is to encourage applications to phenotype and/or perform research on embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium (IMPC) of which the NIH Knockout Mouse Phenotyping Program (KOMP2) is a member. The mission of IMPC is to generate a comprehensive catalogue of mammalian gene function that will provide the foundation for functional analyses of human genetic variation.

BASIC RESEARCH FUNDING OPPORTUNTIES

$150,000 - Friday, October 03, 2025

Cure SMA, US
Cure SMA encourages applications on novel research that will enhance the understanding of SMA disease pathology at the molecular, cellular, and biochemical level; generate key reagents and tools to facilitate drug development and clinical trials; and identify new therapeutic strategies for SMA. Particular interests exist in understanding mechanisms underlying the pathology of disease and/or identifying drug targets synergistic with SMN-upregulating therapeutics for use in older/symptomatic patients.

INNOVATIVE MOLECULAR AND CELLULAR ANALYSIS TECHNOLOGIES FOR BASIC AND CLINICAL CANCER RESEARCH (R61 CLINICAL TRIAL NOT ALLOWED)

Up to $150,000 per year (direct costs). - Friday, October 03, 2025

National Institute of Health
Well-suited applications must propose the development of technologies that offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology.

ADVANCED DEVELOPMENT AND VALIDATION OF EMERGING MOLECULAR AND CELLULAR ANALYSIS TECHNOLOGIES FOR BASIC AND CLINICAL CANCER RESEARCH (R33 CLINICAL TRIAL NOT ALLOWED)

Up to $300,000 per year (in direct costs). - Friday, October 03, 2025

National Institute of Health
The National Cancer Institute (NCI) invites grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic, clinical, or epidemiological cancer research.

EXPLORATORY/DEVELOPMENTAL RESEARCH ON GUILLAIN BARRE SYNDROME (GBS) AND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) (R21 - CLINICAL TRIAL NOT ALLOWED)

The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. - Friday, October 03, 2025

National Institute of Health
This NOFO solicits applications for support of exploratory/developmental studies aimed at accelerating progress toward understanding, preventing or treating Guillain Barre Syndrome (GBS) and/or Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Innovative studies of disease mechanisms, susceptibility factors, model systems, biomarkers and treatments are encouraged.

DoD Prostate Cancer, Idea Development Award

$ 30,500,000 - Friday, August 29, 2025

U.S. Department of Defense (DOD)
The fiscal year 2025 (FY25) Prostate Cancer Research Program (PCRP) Idea Development Award (IDA) supports new ideas that represent innovative approaches to prostate cancer research and have the potential to make an important contribution to the PCRP mission. All applications are required to address one or more of the FY25 PCRP Overarching Challenges.

DoD Prostate Cancer, Clinical Consortium Award

$ 32,500,000 - Friday, August 29, 2025

U.S. Department of Defense (DOD)
The fiscal year 2025 (FY25) Prostate Cancer Research Program (PCRP) Clinical Consortium Award (CCA) provides support to develop, maintain, and enhance the necessary collaborations and resources to rapidly execute phase 2 and/or phase 2-linked phase 1 (phase1/2) prostate cancer clinical trials. The primary intent of the PCRP Clinical Consortium Award is to combine the efforts of leading investigators across multiple institutions to expedite the clinical advancement of novel therapeutic interventions in prostate cancer to decrease the impact of the disease.

Research Grant Awards

$250,000 - Friday, August 22, 2025

Dravet Syndrome Foundation
Research Grant Awards are intended for established, experienced, independent investigators affiliated with a research or academic institution whose proposed projects investigate hypotheses directly related to Dravet syndrome. Proposals are scored according to NIH guidelines based on the quality of preliminary data, research design, feasibility, investigator’s qualifications, and overall impact. Grants are awarded for $250,000 over 2 years (beginning January 1 of each year), with indirect costs not to exceed 10% of the award.

Transformational Science Grant Awards

$500,00 - Friday, August 22, 2025

Dravet Syndrome Foundation
Transformational Science Grants are intended for established, experienced, independent investigators affiliated with a research or academic institution whose proposed projects have substantial preliminary data, investigate hypotheses directly related to Dravet syndrome, and have potential to significantly impact the field of research.

Peter Joseph Pappas Research Grant Program

$200,000 - Friday, August 15, 2025

Preeclampasia Foundation
The ultimate goal of this grant program is to drive research that will eliminate the delivery of pre-term babies as an intervention for severe preeclampsia, HELLP syndrome, and related hypertensive disorders of pregnancy.

The Vision Grant Award Program

Preeclampasia Foundation
Vision Grants are intended to provide initial funding for novel, innovative research by promising young investigators that will advance progress towards detection, prevention, or treatment of preeclampsia, HELLP syndrome, and other hypertensive disorders of pregnancy. Post-doctoral, Clinical Fellows, or Early Stage Investigators only are eligible to apply.

NEA Engagement Grant

$5,000 - Friday, August 15, 2025

The National Eczema Association (NEA)
This award is intended to fuel early-stage ideas by supporting emerging investigators in testing new concepts, piloting experiments or exploring novel data analyses.

NEA Spotlight Grant

$60,000 - Friday, August 15, 2025

The National Eczema Association (NEA)
This award is intended to promote research in topic areas of special interest that relate to NEA’s advancement of our overall research priorities for eczema. The availability of this grant category will be determined on an annual basis; topics of special interest may vary. For 2025, specific areas of research interest include: patient-centered outcomes research.

NEA Champion Grant

$100,000 - Friday, August 15, 2025

The National Eczema Association (NEA)
This award provides funding support for experienced researchers with recognized productivity — either within or outside the eczema field — to conduct highly innovative, cutting-edge investigations related to eczema. Data from this award can then be used to seek additional, larger-scale funding from the National Institutes of Health (NIH) or other funding entities to build on these discoveries.

Childhood Eczema Challenge Grant

$50,000 - Friday, August 15, 2025

The National Eczema Association (NEA)
The Childhood Eczema Challenge Grant is intended to stimulate early and mid-career scientists as they seek to build and sustain careers as research investigators and future thought leaders within this critical field of study

Establishing Antimicrobial Stewardship (AMS)

Budget is limited to $75,000 - Expiry date is April 6, 2022

Pfizer
The purpose of this RFP is to solicit programs that have identified a resource limitation within their healthcare organization that impacts establishment of a holistic and sustainable antimicrobial stewardship (AMS) program...

Improving COVID-19 Outpatient Management

Budget is limited between $50,000 - $100,000 - Expiry date is May 3rd, 2022

Pfizer
Pfizer invites Health Care Organizations based in the countries listed in the Geographic Scope to submit quality improvement (QI) initiatives focused on improving the outpatient management of COVID-19 patients by providing leadership...

Pfizer Announces a Research Grant RFP 2022 Hemophilia ASPIRE

Budget is limited to $50,000 - Expiry date is May 3, 2022

Pfizer
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Immunotherapy in Urothelial Carcinoma

Budget is limited to $50,000 - Expiry date is April 12, 2022

Pfizer
The intent of this RFP is to support independent education initiatives for healthcare professionals involved in the treatment of patients with locally advanced or metastatic urothelial carcinoma...

Cancer Control Research in Persistent Poverty Areas

Budget is limited to $1.5M - Expiry date is July 07, 2022

National Cancer Institute
Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for Cancer Control Research in Persistent Poverty Areas...

Biosimilar User Fee Act Research Grant Clinical Trials Optional

Budget is limited to $5 million - Expiry date is May 10, 2022

U.S. Food & Drug Administration
The Food and Drug Administration (FDA) protects the public health by ensuring that pharmaceutical drug products intended to be marketed in the United States are safe and effective for their intended use...

The Role of Dentistry in the Prevention of Opioid Drug Misuse and Abuse

Budget is limited to $400,000 - Expiry date is May 11, 2022

National Institute of Dental & Craniofacial Research
This Funding Opportunity Announcement (FOA) will support UG3/UH3 phased, cooperative agreement research applications to plan and implement effective interventions or programs to prevent, reduce...

Improved Drug Susceptibility Testing (DST) for Tuberculosis

Budget is limited to $500,000 - Expiry date is July 9, 2022

National Institute of Allergy and Infectious Disease
With 10 million cases and 1.5 million deaths reported every year, Tuberculosis (TB) is one of the leading global infectious disease killers. Among new TB cases, an estimated 4.1% have multidrug-resistant...

Immune Drivers of Autoimmune Disease (IDAD)

Budget is limited to $750,000 - Expiry date is July 02, 2022

National Institute of Allergy and Infectious Disease
This Funding Opportunity Announcement (FOA) invites applications to participate in the Immune Drivers of Autoimmune Disease (IDAD) cooperative research program, which will focus on defining the immunologic states and dynamics that drive autoimmune disease...

Young Investigator Award - Raising Standards Through Education & Training

3,000 € for each prize - Application deadline - April 30, 2022

European Association for Cardio-Thoracic Surgery
To stimulate research, the EACTS has instituted prizes for the best manuscripts on topics of clinical or experimental research in the fields of Thoracic Surgery, Cardiac Surgery, and Congenital Heart Disease presented by young investigators at the Annual Meeting...

Accelerating progress in Celiac disease research

BUDGET INFORMATION: Not specified - Deadline on January 12, 2022

National Institute of Health
Notice of special interest – accelerating progress in celiac disease research funding opportunity. This supports research on the etiology and pathogenesis of celiac disease, identification of therapeutic targets, and development of preventative or disease ameliorating therapies and strategies. Each institute has its own research priorities.

Analysis of post-mortem brain tissue from the Autism Brain Net collection

BUDGET INFORMATION: USD 300,000 to USD 1 million / year (up to 2 years) - Expiry date: 10 January 2022

Simons Foundation
The Simons Foundation, under its Autism Research Initiative, invites applications for its analysis of post-mortem brain tissue from the Autism Brain Net collection funding opportunity...

CREID Pilot Research Program: 2022 Call for Applications

BUDGET INFORMATION: TBA - Expiry date: January 31, 2022

Centers for Research in Emerging Infectious Diseases
The CREID Network Pilot Research Program supports, trains, and mentors the next generation of emerging infectious disease researchers. This program will help develop capacity for emerging infectious disease research around the world through the performance of scientific research projects.

Elucidating the role of nutrition in care and development of preterm infants

BUDGET INFORMATION: USD 2,500,000 - Expiry date: March 30, 2022

National Institute of Health
The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its elucidating the role of nutrition in care and development of preterm infants (R01 clinical trial optional) funding opportunity. This supports research addressing priority...

Novel immune strategies to enhance beta cell replacement therapies for type 1 diabetes (T1D)

BUDGET: USD 350,000 per year for a maximum of two years. - Expiry date: October 25, 2021

Juvenile Diabetes Research Foundation
JDRF invites letters of intent for its novel strategies to enhance beta cell replacement therapies for type 1 diabetes (T1D) funding opportunity. This supports preclinical and clinical studies from academic or industry applicants with innovative and incremental immune...

Nutrition in the areas of health, education, training, and research

BUDGET: To be defined - Deadline for application: Jan 15, 2022

Allen Foundation Inc.
To make grants to fund relevant nutritional research. To support programs for the education and training of mothers during pregnancy and after the birth of their children, so that good nutritional habits can be formed at an early age. To assist in the training of persons to work as educators and demonstrators of good nutritional practices. To encourage the...

Global brain and nervous system disorders research across the lifespan (LMIC)

Budget will be defined according to the project need - Dur for application: Dec 9, 2021

National Institute of Health
This encourages innovative, collaborative research projects between US and low- and middle-income country scientists, on brain and other nervous system function and disorders throughout life, relevant to LMICs. This includes neurological, mental, behavioural...

Global Obesity ASPIRE

USD 250,000 up to 3 years - Deadline for application: February 2022

Pfizer
Pfizer invites letters of intent for its ASPIRE global obesity grant. This supports basic science, preclinical research and clinical research, animal experimentation related to human biology and physiological, cellular, molecular and translational research regarding obesity.

Emerging Global Leader Award in LMIC (NIH - K43)

Award budgets are composed of salary and other expenses - Due date: October 3, 2021

National Institute of Health
The purpose of the Fogarty Emerging Global Leader Award is to provide research support and protected time (three to five years) to an early career research scientist from a low- or middle-income country (LMIC) who holds a junior faculty position at an LMIC academic or research institution, as defined by the World Bank...

Comparative effectiveness of multimodal interventions to prevent osteoporotic fractures

BUDGET INFORMATION: $40 million up to 5 years - Due date for application: Jan 11, 2022

Patient-Centered Outcomes Research Institute
The Patient-Centered Outcomes Research Institute invites letters of intent for its call on comparative effectiveness of multimodal interventions to prevent osteoporotic fractures. This supports comparative effectiveness research projects that focus on multimodal ...

Spinal cord injury

€100,000 / year for up to three years - Deadline for application is Nov 2, 2021

Wings for Life
The Wings for Life invites executive summaries for its project research grants. These support basic or clinical research projects related to spinal cord injury with the perspective to improve outcomes. Projects may be in the following areas: • basic research projects – nerve regeneration and plasticity, neuronal and glial protection, functional deficits induced by...

Standard awards in Alzheimer's disease research

BUDGET INFORMATION: USD 300,000 for 3 years - Due date: Nov 1, 2021

BrightFocus Foundation
These support research that accelerate the understanding of the biological mechanisms underlying Alzheimer’s disease and related dementias as well as innovative approaches to better diagnose, prevent, or delay the progress of the disease. The awards are designed for researchers who have already generated some amount of preliminary data but are...

Critical gaps and challenges and potential breakthroughs in type 1 diabetes

Budget & duration of funding are variable - Due date for application is Nov 2, 2021

Juvenile Diabetes Research Foundation
Strategic research agreements. These enable single or multiple investigators to address critical gaps and challenges and potential breakthroughs in type 1 diabetes research. Clinical trials may also be supported.

HR+ HER2- Metastatic Breast Cancer Medical Management

Multi-centre programs can request up to $250,000 & uni-lateral request can apply up to $50,000. - Due date is Sep 22, 2021

Pfizer
Healthcare professionals need to understand the latest scientific data in order to make evidence-based treatment decisions and provide optimal care for patients with ER+ HER2- metastatic breast cancer.

Burden of Pneumococcal Disease - Analysing Local Surveillance Data (Middle East)

BUDGET INFORMATION: $40,000 for a 1-year project - Due date is Sep 22, 2021

Pfizer
This supports the review and analysis of retrospective, local source surveillance of the pneumococcal disease burden or serotype distribution, whether in children or adults, as determined before, during or following the implementation of a pneumococcal...

Care and treatment of children with lung diseases

Research budget is €15,000 - Due date for application is Dec 1, 2021

Society for Pediatric Pneumonology
Johannes Wenner prize. This supports research projects of society members in relation to the improvement of care and treatment of children with lung diseases.

Macular Degeneration Research Grant

Budget allowed is $200,000 per year with a total of $600,000 over three years - Due date for application is Dec 3, 2021

BrightFocus Foundation
Bright Focus provides research funds for U.S. domestic as well as international researchers pursuing pioneering research leading to greater understanding, prevention, and treatment of age-related macular degeneration.

High Resolution Mapping of Biomolecules in Brain Cells in Aging and Alzheimer’s Disease

Budget allowed is $500,000 in direct costs per year. - Due date for application is Oct 29, 2021

National Institute of Health
R01 funding mechanism to support discrete, specified, and circumscribed projects on novel molecular imaging approaches to establish high-resolution mapping of biomolecules in brain cells and regions during the course of aging and Alzheimer’s disease (AD). This FOA...

Alopecia areata, atopic dermatitis and vitiligo

Budget: USD 175,000 - Due date for application is Aug 16, 2021

Pfizer
Preclinical, clinical and outcomes research aimed at increasing medical knowledge in alopecia areata, atopic dermatitis or vitiligo.

HIV-associated Non-Communicable Diseases Research at Low-and Middle-Income Country Institutions (NIH - R21)

BUDGET INFORMATION: $150,000 / year & up to $275.000 / 2 years. - Due date for application: Dec 9, 2021

National Institute of Health
The goals of this program are to support locally relevant research in critical areas of HIV-associated non-communicable diseases (NCDs) at Low- and Middle- Income Country (LMIC) Institutions, to enhance research capacity, and to build a network of researchers...

New strategies in diabetes

BUDGET INFORMATION: €150,000 for 1 year - Deadline for application: Dec 2, 2021

European Association for the Study of Diabetes
EFSD/Lilly exploring and applying new strategies in diabetes expand the program. This supports diabetes research projects on potential strategies that can be implemented in Europe and rolled out in low and middle-income countries to favor the improvement of quality of care for people living with diabetes.

Sexual reproductive health and rights in (MENA) region

Budget ranges from £300,000 to £1.38 million for two to five years - Due date for application is Aug 26, 2021

AmplifyChange
This aims to contribute to the development of stronger and more inclusive movements advocating for sexual reproductive health and rights in sub-Saharan Africa, south Asia and Middle East and north Africa (MENA) region.

Horizon 2021 - Staying Healthy (LMIC countries)

Budget research allowed is €10,000,000 - Due date for application is Sep 21, 2021

Horizon Europe. Global Challenges and European Industrial Competitiveness
Staying healthy call. This supports projects that set out a credible pathway to contributing to staying healthy in a rapidly changing society.

Funding Research on Neurofibromatosis

Budget of USD 40,000 for preclinical drug testing studies & up to USD 85,000 for animal-based preclinical drug testing studies. - Due date for application is Nov 2021

Children's Tumor Foundation
The Children’s Tumor Foundation invites letters of intent for its drug discovery initiative registered reports award program. This supports early-stage testing of candidate drug therapies for the treatment of neurofibromatosis.

Funding Opportunity in Paediatric Cancer

Budget allowed is USD 5 million for four years - Due date for application is Aug 5, 2021

Alex's Lemonade Stand Foundation for Childhood Cancer
Research addressing the most intractable issues in paediatric cancer. Projects should fall under the following research themes: developmental origins of paediatric cancers; drugging currently undruggable paediatric cancers; developing novel immunotherapies; or discovery and development of novel paediatric cancer drug targets.

Stimulating Innovative Research on Drug Discovery

Budget ranges between 40,000 € - 450,000 € per year up to 3 years - Due time for application is Aug 31, 2021

MERCK
Research grants to stimulate innovative research in challenging areas of future importance. You may apply for more than one grant or submit your application for more than one focus topic: Drug Discovery, Real time testing and sensors, Nanoparticle for nucleic acid...

Funding Opportunity in Cancer Research

Budget allowed is USD 400,000 for two years - Due date for applications is Sep 30, 2021

American Association for Cancer Research
MPM oncology charitable foundation transformative cancer research grants. These support early- to mid-career researchers in undertaking paradigm-shifting cancer research that might not be funded through conventional channels.

Research grants on Down’s syndrome

BUDGET INFORMATION: €40,000 OR €80,000 - Due date for application is Aug 9, 2021

Jérôme Lejeune Foundation
Research projects on Down’s syndrome. Applications may cover fundamental, translational, epidemiological, clinical research, neurobiology and pharmacology, genetic, genomic, induced pluripotent stem cells, neuropsychology techniques or data analysis. Priority will be given to clinical research projects.

Closing knowledge gaps in transthyretin cardiomyopathy (Middle East)

BUDGET INFORMATION: USD 20,000 - Due date for application is July 15, 2021

Pfizer
Closing knowledge gaps in transthyretin cardiomyopathy in emerging markets under its competitive grants program. This supports projects that focus on closing the knowledge gaps in transthyretin cardiomyopathy within Asia, Latin America, Africa, and Middle East. Projects should focus on: educating healthcare providers on the subject matter; creating strategies...

Funding Opportunity on COVID-19 Epidemiology Research

Budget allowed is $60000 for a 1-year project - Proposal due is July 25, 2021

Pfizer
COVID-19 Epidemiology Research Projects that will be considered for Pfizer support should be focusing on SARS-CoV-2 Variants epidemiology, T-cell responses to SARS-CoV-2 – from natural infection or Paediatric COVID-19 epidemiology – in children and adolescents <16 years, characterization of disease burden and epidemiology.

Funding Opportunity: Challenges related to COVID-19

Budget Information: USD 100,000 - Deadline for receiving applications is 5 July, 2021

The World Academy of Science (TWAS)
IsDB-TWAS Joint Research & Technology Transfer Grant 2021: Quick-Response Research on COVID-19.This supports technologists and researchers from IsDB member countries in collaborating to address challenges directly and indirectly related to COVID-19.

Alpha-1 Antitrypsin Deficiency Research

Budget Information: USD 225,000 - Due date for application is Sep 24, 2021

Alpha-1 Foundation
John W Walsh translational research award supports research aimed at finding a cure for alpha-1 antitrypsin deficiency.

Appropriate immunization in patients with immune-mediated inflammatory conditions

Budget allowed is up to $150,000 - Proposal due is July 12, 2021

Pfizer
Appropriate immunization in patients with immune- mediated inflammatory conditions. This supports quality or process improvement projects, and medical education and patient awareness initiatives aimed at addressing the vaccination needs and gaps among patients...

Global Infectious Disease Research Training Program

Budget allowed is $230,000 per year​ - Due date for application is July 03, 2021

National Institute of Health
Support research-training programs that focus on: - Major endemic or life-threatening emerging infectious diseases, Neglected tropical diseases, Infections that frequently occur as co-infections in HIV infected individuals or Infections associated with non- communicable disease conditions of public health importance in LMICs.

Funding Research On Osteoarthritis

Budget Information: USD 50,000 - Proposal due June 1, 2021

American Orthopaedic Society for Sports Medicine
This opportunity fosters research in the areas of early OA and prevention of OA progression. Proposed studies need not relate specifically to sports injuries. Research priorities include: Investigating the pre-osteoarthritic joint; Examining prevention or treatment of posttraumatic OA; Determining the relationship between injury and OA; Enhancing clinical...

Funding Research On Cyctinosis

Budget Information: Not specified - Proposal deadline October 13, 2021

Cystinosis Research Foundation
This supports research to improve the immediate care of children and adults with cystinosis and to develop a new understanding and treatment of cystinosis to help these patients in the future.

Funding Research On Myositis

$100,000 per year for 2 years - Letters of intent due by 15 May 2021; full applications due by 30 June 2021

The Myositis Association
The Myositis Association has a competitive grant program for innovative pilot research into any type of immune- mediated myositis...

Inflammatory Bowel Disease

Two grants of 10,000 Euros each - Proposal due Jun 30, 2021

International Organization For the Study of Inflammatory Bowel Disease
These support members of the organisation in conducting research relevant to inflammatory bowel disease. The aim is to fund two clinical and two basic science projects.

WHO International health regulations (2005) and health security preparedness research call

Budget Information: from 5,000 up to 10,000 USD - Due date: June 25, 2021

World Health Organization
This supports projects that document, synthesise and disseminate evidence of capacities for international health regulation (2005) implementation, health security and health emergency preparedness, as well as supporting the collaborative development and advancement...

Atrial Fibrillation and Venous Thromboembolism

Budget allowed is $150,000. - Due date for application is Sep 01, 2021

Bristol-Myers Squibb/Pfizer Alliance
Projects that will be considered for Pfizer support will focus on improving the care of patients by addressing knowledge gaps in following areas. Grant proposals can address either Atrial Fibrillation (AF) or Venous Thromboembolism (VTE) or both areas...

Osteoarthritis and Osteoarthritis Pain

Budget Information: USD 200,000 - Deadline: August 20, 2021

Pfizer
Supports research focusing on osteoarthritis and chronic pain associated with osteoarthritis, as well as patient- centered standard of care and management. Research may include pain and function, the biopsychosocial aspects of the disease, the complexities, and challenges of care, and the future of osteoarthritis and osteoarthritis pain management. Programs...

Cancer Prevention, Detection, Diagnosis & Treatment Technologies for Global Health

Budget Information: USD 475.000 over five years - Full Application due 02 June 2021

National Institute of Health
This supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). The aim is to adapt, apply and validate existing or emerging technologies into a new generation of user-friendly...

3 Award Opportunities: Cardio-Thoracic Surgery

The Award is €3,000 for each prize - Closing date: 31 April 2021

European Association for Cardio-Thoracic Surgery
Three award opportunities from the European Association for Cardio-Thoracic Surgery that you may apply for.

Cardio-Thoracic Surgery Young investigator awards

Award amount: 3,000 € - Closing date: April 30, 2021

European Association for Cardio-Thoracic Surgery
Manuscripts on topics of clinical or experimental research in the fields of thoracic surgery, cardiac surgery and congenital heart disease, presented by young investigators at the association’s annual meeting.

Cardio-Thoracic Surgery Hans G Borst award for thoracic aortic surgery

Award amount: 5,000 € - Closing date: April 30, 2021

European Association for Cardio-Thoracic Surgery
This stimulates advanced clinical or experimental research in the field of thoracic aortic surgery by young investigators, as documented by a presentation during the annual meeting of the association.

Dravet Syndrome

Allowed Budget is USD 150,000. - Due date is Sep 10, 2021

Dravet Syndrome Foundation
The Dravet Syndrome Foundation invites applications for its research grants. These support research projects investigating hypotheses directly related to Dravet syndrome. The priority areas...

Neurodegenerative diseases and psychiatric disorders award

Award & Research budget allowed is €750,000 - Due date for application is June 30, 2021

Fondation Roger De Spoelberch
This recognizes a clinical and basic scientific research project within the field of neurodegenerative diseases and psychiatric disorders.

Lupus and Autoimmunity Research Award

USD 250,000 per year for up to four years. - Due date is June 1, 2021

Lupus Research Alliance
William E Paul distinguished innovator award in lupus and autoimmunity. This supports novel research into the fundamental causes of lupus to provide new directions toward a cure. Novel, hypothesis or discovery-driven proposals using clinically relevant models in lupus research are welcome. Proposals must aim to uncover the fundamental causes of lupus and...

COVID - 19: DAILY UPDATES

By Guillian Mohney, George Citroner & Dana K. Cassel

Healthline
HEALTHLINE and their reporter's teams are doing an outstanding job, particularly, in these difficult challenging existential times. Covid-19 pandemic is ravaging the world reaping lives without distinction between races, languages, nationalities, social level, faith, and religion. Thanks to HEALTHLINE for the great job they are offering to the community and for the daily updates spreading the right information and saving lives.

Paediatric Gastroenterology, Hepatology and Nutrition Research

Research Budget is €50,000 - Due Date is July 31, 2021

European Society for Paediatric Gastroenterology, Hepatology and Nutrition
These enable members to undertake research activities and network among centers at an international level. Activities may include interactive educational events and clinical networks. Proposals relevant to the society’s activities, such as the validation of guidelines, or clinical networks for testing treatment regimes or disease management, are encouraged.

Malignant lymphoma, malignant lymphoid neoplasia and related malignant blood diseases

BUDGET INFORMATION: €1.5 million for up to four years - Project idea due July 14, 2020

Lymph & Co Foundation
These support research that may lead the way to the cure or the improved therapeutic management of lymphoma. Basic, translational or clinical research on malignant lymphoma, malignant lymphoid neoplasia and related malignant blood diseases is supported.